Durvalumab
Phase 2Recruiting 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Early Small (cT1N0) Triple Negative Breast Cancer
Conditions
Early Small (cT1N0) Triple Negative Breast Cancer
Trial Timeline
Dec 6, 2021 → Jun 1, 2026
NCT ID
NCT05215106About Durvalumab
Durvalumab is a phase 2 stage product being developed by AstraZeneca for Early Small (cT1N0) Triple Negative Breast Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05215106. Target conditions include Early Small (cT1N0) Triple Negative Breast Cancer.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06992609 | Phase 3 | Recruiting |
| NCT06826677 | Pre-clinical | Completed |
| NCT05925530 | Phase 2 | Active |
| NCT04944173 | Phase 2 | Withdrawn |
| NCT05924880 | Phase 3 | Completed |
| NCT05617963 | Phase 2 | Recruiting |
| NCT05683977 | Pre-clinical | Active |
| NCT05303532 | Phase 3 | Recruiting |
| NCT05215106 | Phase 2 | Recruiting |
| NCT04416633 | Approved | Completed |
| NCT05933044 | Pre-clinical | Completed |
| NCT04765709 | Phase 2 | Terminated |
| NCT04667312 | Pre-clinical | Completed |
| NCT04062708 | Phase 2 | Active |
| NCT04230408 | Phase 2 | Completed |
| NCT04441138 | Phase 2 | Terminated |
| NCT05267392 | Phase 1/2 | UNKNOWN |
| NCT04543110 | Phase 2 | UNKNOWN |
| NCT04716946 | Phase 2 | Active |
| NCT04642469 | Phase 3 | Completed |
Competing Products
20 competing products in Early Small (cT1N0) Triple Negative Breast Cancer